Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAOX | Q6QHF9 | 5/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | F13A1 | P00488 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | CA4 | P22748 | 2/20 | 0.50 |
| ▸ | CA6 | P23280 | 2/20 | 0.50 |
| ▸ | CA5A | P35218 | 2/20 | 0.50 |
| ▸ | THPO | P40225 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.50 |
| ▸ | CASP2 | P42575 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3143903 | 0.96 | PAOX (0.56) | PAOXTDP1CA12F13A1CA2 | |
| SCHEMBL2128045 | 0.96 | PAOX (0.52) | PAOXTDP1CA12F13A1CA2 | |
| SCHEMBL27839874 | 0.92 | PAOX (0.49) | PAOXTDP1CA12F13A1CA2 | |
| SCHEMBL7018961 | 0.82 | ALOX15 (0.52) | PAOXTDP1CA12F13A1CA2 | |
| SCHEMBL11793263 | 0.82 | CYP2C9 (0.52) | PAOXTDP1CA12CA2ALOX15 | |
| SCHEMBL27860781 | 0.81 | PAOX (0.42) | PAOXCYP1A2ALOX15THPOMEN1 | |
| SCHEMBL22491057 | 0.80 | CYP2C9 (0.50) | PAOXTDP1CA12CA2ALOX15 | |
| SCHEMBL5507927 | 0.79 | PAOX (0.55) | PAOXTDP1CA12F13A1CA2 | |
| Spermine SCHEMBL6422290 | 0.79 | PAOX (0.69) | PAOXTDP1CA12F13A1CA2 | |
| Spermine SCHEMBL625285 | 0.79 | PAOX (0.69) | PAOXTDP1CA12F13A1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 368 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12578322-B2 | Methods and consumer products for detecting a metabolite | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2026-03-17 | — | — | US | claimed |
| US-20260063638-A1 | METHODS FOR THE DETECTION AND TREATMENT OF LUNG CANCER | UNIV TEXAS (US) | 2026-03-05 | — | — | US | claimed |
| EP-4237090-B1 | METHODS FOR THE DETECTION AND TREATMENT OF OVARIAN CANCER | UNIV TEXAS (US) | 2026-02-18 | — | — | EP | claimed |
| US-12504430-B2 | Methods for the detection and treatment of lung cancer | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-12-23 | — | — | US | claimed |
| US-20250273344-A1 | METHODS FOR THE DETECTION AND TREATMENT OF LUNG CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2025-08-28 | — | — | US | claimed |
| CN-119968213-A | Methods for detecting and treating ovarian cancer | 德州大学系统董事会 | 2025-05-09 | — | — | CN | claimed |
| US-20250138016-A1 | METHODS FOR THE DETECTION AND TREATMENT OF OVARIAN CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2025-05-01 | — | — | US | claimed |
| EP-4528741-A2 | METHODS FOR THE DETECTION AND TREATMENT OF LUNG CANCER | Board of Regents, The University of Texas System (US) | 2025-03-26 | — | — | EP | claimed |
| EP-4518832-A1 | CHONDROITIN- AND COLLAGEN PEPTIDE-BASED METHODS FOR SLOWING DOWN AGING AND EXTENDING LIFESPAN | Ageless Sciences, Inc. (US) | 2025-03-12 | — | — | EP | claimed |
| CN-119173247-A | Methods for slowing aging and prolonging life based on chondroitin and collagen peptides | 不老科学公司 | 2024-12-20 | — | — | CN | claimed |
| US-20100151585-A1 | Method for determining degree of negative effect of macrophages on vertebrate | HAMAOKI MASARU | 2010-06-17 | — | — | US | claimed |
| US-7700741-B2 | High affinity anti-N1,N12-diacetylspermine monoclonal antibody | TRANS GENIC INC. (JP) | 2010-04-20 | — | — | US | claimed |
| US-20100093006-A1 | HIGH AFFINITY ANTI-N1,N12-DIACETYLSPERMINE MONOCLONAL ANTIBODY | NAGASE YUSEI | 2010-04-15 | — | — | US | claimed |
| US-7687231-B2 | Method for determining degree of negative effect of macrophages on vertebrate | YAMASA CORPORATION (JP) | 2010-03-30 | — | — | US | claimed |
| US-20090298098-A1 | N1, N12-DIACETYLSPERMINE AS TUMOR MARKER | TOKYO METROPOLITAN ORGANIZATION FOR MEDICAL RESEARCH (JP) | 2009-12-03 | — | — | US | claimed |
| EP-2098864-A1 | METHOD OF IMMUNOASSAYING URINARY COMPONENT AND REAGENT TO BE USED THEREFOR | Tokyo Metropolitan Organization for Medical Research (JP) | 2009-09-09 | — | — | EP | claimed |
| US-20070202554-A1 | Method for determining degree of negative effect of macrophages on vertebrate | YAMASA CORPORATION (JP) | 2007-08-30 | — | — | US | claimed |
| US-20070161059-A1 | N1,n12-diacetylspermine as tumor marker | TRANS GENIC INC. (JP) | 2007-07-12 | — | — | US | claimed |
| US-20060166297-A1 | High affinity anti-N¹,N¹²-diacetylspermine monoclonal antibody | TRANS GENIC INC. (JP) | 2006-07-27 | — | — | US | claimed |
| EP-1610127-A1 | N1,N12-DIACETYLSPERMINE AS TUMOR MARKER | Trans Genic Inc. (JP) | 2005-12-28 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260063638-A1 | METHODS FOR THE DETECTION AND TREATMENT OF LUNG CANCER | CA11, CA12, CA13 | PAOX 4572/4885TDP1 2470/4885CA12 2/4885 |
| US-12578322-B2 | Methods and consumer products for detecting a metabolite | SHBG, OXGR1, OGG1 | PAOX 1174/4885TDP1 3016/4885CA12 3041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.